Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GLPG 3067

Drug Profile

GLPG 3067

Alternative Names: ABBV 3067; GLPG-3067; GLPG0367

Latest Information Update: 18 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
  • Developer AbbVie; Galapagos NV
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cystic fibrosis

Most Recent Events

  • 03 Sep 2019 Phase-II clinical trials in Cystic fibrosis (Combination therapy) in Hungary (PO) (EudraCT2019-000750-63) (NCT03969888)
  • 03 Sep 2019 Phase-II clinical trials in Cystic fibrosis (Monotherapy) in Hungary (PO) (EudraCT2019-000750-63) (NCT03969888)
  • 31 May 2019 AbbVie plans a phase II trial for Cystic fibrosis in USA in August 2019 (NCT03969888)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top